Ind-Swift Limited (BOM:524652)

Market Cap	850.39M
Revenue (ttm)	5.15B
Net Income (ttm)	2.83B
Shares Out	54.16M
EPS (ttm)	52.33
PE Ratio	0.30
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,760
Average Volume	21,537
Open	14.86
Previous Close	14.98
Day's Range	14.86 - 17.82
52-Week Range	12.00 - 34.49
Beta	-0.77
RSI	42.60
Earnings Date	Aug 8, 2025

About Ind-Swift

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicine...

• Industry: Pharmaceutical Preparations
• Founded: 1983
• Employees: 1,054
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524652

Financial Performance

In 2024, Ind-Swift's revenue was 5.15 billion, an increase of 2.54% compared to the previous year's 5.02 billion. Earnings were 2.83 billion, an increase of 1891.74%.